Preclinical data have demonstrated that administration of TLR7/8 and TLR9 agonists in combination with current anticancer regimens boosts the local and systemic antitumor immune response, promotes tumor cell killing and contributes to better outcomes, providing the rationale to use TLR agonists as adjuvants with ICBs [245–249]. Here, TLR9 is linked to neoplasm.